B-type natriuretic peptide: from bench to bedside.
Adams
Kirkwood F
KF
Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7075, USA. kfa@med.unc.edu
Mathur
Vandana S
VS
Gheorghiade
Mihai
M
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000502:physiology* / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004280:Dobutamine / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D045283:Natriuretic Agents / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017461:Receptors, Atrial Natriuretic Factor / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004232:Diuretics; D045283:Natriuretic Agents; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain; D009599:Nitroprusside; D004280:Dobutamine; D009320:Atrial Natriuretic Factor; D017461:Receptors, Atrial Natriuretic Factor; D005996:Nitroglycerin